DrugPatentWatch Database Preview
TPOXX Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Tpoxx patents expire, and what generic alternatives are available?
Tpoxx is a drug marketed by Siga Technologies and is included in one NDA. There are six patents protecting this drug.
This drug has sixty-nine patent family members in twenty-one countries.
The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
Summary for TPOXX
| International Patents: | 69 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 15 |
| Patent Applications: | 14 |
| DailyMed Link: | TPOXX at DailyMed |
Generic Entry Opportunity Date for TPOXX
Generic Entry Date for TPOXX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for TPOXX
| 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide |
| 458T318 |
| 816458-31-8 |
| 869572-92-9 |
| AKOS030260536 |
| AN-27268 |
| Benzamide, N-((3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)-, rel- |
| Benzamide, N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-, rel- |
| CHEMBL1257073 |
| CS-3464 |
| DB12020 |
| F925RR824R |
| HY-14805 |
| N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide |
| N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide |
| N-(dioxo[?]yl)-4-(trifluoromethyl)benzamide |
| N-[(3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)benzamide |
| SCHEMBL404743 |
| SIGA 246 |
| SIGA-246 |
| ST 246 |
| ST-246 |
| Tecovirimat |
| Tecovirimat [USAN:INN] |
| UNII-F925RR824R |
| ZINC35323125 |
US Patents and Regulatory Information for TPOXX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TPOXX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 241731 | Start Trial |
| Argentina | 083435 | Start Trial |
| Japan | 2010535705 | Start Trial |
| Chile | 2012002621 | Start Trial |
| Mexico | 2012010859 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
